APOE and COVID-19: In COVID-19 patients, we estimated a proper excess of 0.12 ± 0.06 mg/dl for NEFAs (p = 0.04), and reductions of 0.36 ± 0.10 mmol/L in HDL cholesterol (p < 0.01) and 116.05 ± 45.49 ug/ml in Apolipoprotein E (ApoE) concentrations (p = 0.01).